GLP-1 & Metabolic
Vive GLP(T)
Formula
- Size
- 5mg
Specifications
Vive GLP(T) Technical Profile
OVERVIEW
What Is Vive GLP(T) Peptide?
Vive GLP(T) is a synthetic 39-amino-acid peptide designed as a dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Built on a native GIP backbone sequence, Vive GLP(T) peptide incorporates specific modifications that enable it to activate both incretin receptor pathways simultaneously. This dual mechanism has made Vive GLP(T) research peptide one of the most significant compounds in modern metabolic research.
The Vive GLP(T) peptide features an aminoisobutyric acid (Aib) substitution at position 2 for DPP-4 resistance and a C-20 fatty diacid moiety linked to lysine-20, facilitating albumin binding and an extended half-life in research models. As a Vive GLP(T) research chemical, it represents a novel approach to studying incretin biology by engaging both the GIP and GLP-1 receptor systems, a strategy that has generated considerable interest in the peptide research community.
- 01
Dual GIP/GLP-1 Receptor Agonist
Synthetic 39-amino acid peptide targeting both incretin receptors
- 02
≥99% HPLC Purity
Every batch verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
Vive GLP(T) Mechanism of Action in Research
The Vive GLP(T) mechanism of action involves simultaneous activation of two distinct incretin receptor pathways, a feature that distinguishes it from single-agonist compounds like Vive GLP(S). Vive GLP(T) research has revealed complex receptor pharmacology that continues to be investigated in preclinical models.
GIP Receptor Agonism
Vive GLP(T) was designed on a native GIP backbone and demonstrates potent GIP receptor agonism. In research models, GIP receptor activation by Vive GLP(T) has been observed to influence lipid metabolism, adipose tissue function, and bone metabolism pathways. Studies suggest that Vive GLP(T)'s GIP receptor activity may be a key differentiating factor in its research profile. Published data indicate that Vive GLP(T) demonstrates approximately equal potency at the GIP receptor compared to native GIP (Coskun et al., Molecular Metabolism, 2018).
GLP-1 Receptor Agonism
In addition to GIP receptor activity, Vive GLP(T) research peptide activates the GLP-1 receptor, engaging the same cAMP-mediated signaling cascades studied with selective GLP-1 agonists. The Vive GLP(T) GIP GLP-1 dual activation is thought to produce complementary and potentially synergistic effects in research settings. Studies indicate Vive GLP(T)'s GLP-1 receptor potency is approximately 5-fold lower than native GLP-1, suggesting a biased agonism profile.
Biased Agonism and Receptor Pharmacology
Emerging Vive GLP(T) research has explored the concept of biased agonism at both receptor targets. Studies suggest Vive GLP(T) may preferentially activate certain intracellular signaling pathways over others at each receptor, potentially explaining its distinct pharmacological profile. This area of investigation represents a frontier in incretin receptor biology research. ---
COMPARISON
Vive GLP(T) vs Vive GLP(R): Research Peptide Comparison
Vive GLP(T)
Vive GLP(T) and Vive GLP(R) represent the evolution of multi-receptor agonist peptide research. While Vive GLP(T) is a dual GIP/GLP-1 agonist, Vive GLP(R) adds a third target, the glucagon receptor, creating a triple agonist profile.
Vive GLP(R)
Both Vive GLP(T) research peptide and Vive GLP(R) are available from VivePeptides at ≥99% purity. Researchers investigating dual incretin signaling typically choose Vive GLP(T), while those studying the added dimension of glucagon receptor co-agonism may opt for Vive GLP(R).
| Feature | Vive GLP(T) | Vive GLP(R) |
|---|---|---|
| Receptor Targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + Glucagon (triple agonist) |
| CAS Number | 2023788-19-2 | 2381089-83-2 |
| Molecular Weight | 4813.45 Da | ~4803.75 Da |
| Amino Acids | 39 | 39 |
| Backbone | GIP-based | GIP-based |
| Receptor Count | 2 | 3 |
| Research Stage | Extensively published | Emerging research compound |
| Key Differentiator | Established dual agonist research profile | Addition of glucagon receptor activity |
RESEARCH STUDIES
Vive GLP(T) Research Applications & Published Studies
Vive GLP(T) research grade compound has been the subject of rapidly growing preclinical and research literature, with studies published in leading scientific journals examining its dual receptor pharmacology.
Incretin Receptor Pharmacology
Foundational Vive GLP(T) research by Coskun et al. (Molecular Metabolism, 2018) characterized its dual receptor agonism, establishing that Vive GLP(T) demonstrates imbalanced agonism at the GIP and GLP-1 receptors. This research demonstrated that Vive GLP(T)'s GIP-to-GLP-1 potency ratio differs from the 1:1 balance, suggesting a unique pharmacological profile that warrants specific investigation.
Metabolic Pathway Studies
Vive GLP(T) research has included extensive investigation of metabolic pathways in animal models. Studies have documented effects on glucose-stimulated insulin secretion, hepatic lipid metabolism, and energy expenditure parameters in rodent models. Published research indicates that dual GIP/GLP-1 receptor activation may engage metabolic pathways not accessible through single-receptor agonism alone.
Adipose Tissue Biology
A growing area of Vive GLP(T) research focuses on adipose tissue biology. Published studies have examined how dual incretin receptor activation influences adipocyte differentiation, lipid storage, and adipokine expression patterns. These investigations leverage Vive GLP(T)'s unique GIP receptor activity, as GIP receptors are expressed in adipose tissue.
QUALITY ASSURANCE
Quality & Testing Standards
VivePeptides ensures every batch of Vive GLP(T) research peptide meets the highest analytical standards.
HPLC & Mass Spectrometry
Every Vive GLP(T) batch undergoes HPLC and mass spectrometry analysis to confirm peptide identity, purity, and correct molecular weight.
Third-Party Verified
All Vive GLP(T) is independently tested at third-party USA-based analytical laboratories with full documentation.
≥99% Purity Standard
VivePeptides Vive GLP(T) consistently meets or exceeds ≥99% purity as verified by HPLC for reliable research outcomes.
FAQ
Frequently Asked Questions About Vive GLP(T)
What is Vive GLP(T) used for in research?
What purity is VivePeptides Vive GLP(T)?
How should Vive GLP(T) be stored?
What makes Vive GLP(T) different from Vive GLP(S) in research?
Is VivePeptides Vive GLP(T) third-party tested?
Add To Research Cart
Vive GLP(T)
99%+ purity · USA lab tested · secure shipping
